Investor Alert

Dow Jones Newswires Archives | Email alerts

Aug. 15, 2022, 2:42 a.m. EDT

Enhertu significantly delayed breast cancer progression in trial, AstraZeneca says

Watchlist Relevance

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    AstraZeneca PLC (AZN)

or Cancel Already have a watchlist? Log In

By Kyle Morris

AstraZeneca PLC said Monday that its Enhertu drug significantly delayed metastatic breast cancer progression in a Phase 3 trial, reinforcing the results of a prior trial.

The Anglo-Swedish pharma giant /zigman2/quotes/203048482/delayed UK:AZN +1.54% said results from the Destiny-Breast02 Phase 3 trial of Enhertu–trastuzumab deruxtecan–showed the trial met the primary endpoint, demonstrating a significant and clinically meaningful improvement in progression-free survival in patients.

Enhertu is being jointly developed and commercialized by AstraZeneca and Daiichi Sankyo Ltd.

Write to Kyle Morris at kyle.morris@dowjones.com

UK : U.K.: London
10,076.00 p
+153.00 +1.54%
Volume: 2.24M
Sept. 28, 2022 4:35p
P/E Ratio
Dividend Yield
Market Cap
£153.76 billion
Rev. per Employee

This Story has 0 Comments
Be the first to comment
More News In
Dow Jones Newswires

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.